Suicide Risk with Singulair
In the Friday, March 28th issues of MedPage and Physician's First Watch the alert regarding suicide risk and treatment with Singulair was published. The FDA has undertaken a study of Singulair (montelukast) a popular asthma and allergy drug to examine the association between the drug and behavior and mood changes, suicidal thoughts and suicidal behaviors. The FDA indicated that the study may take months, but that the initiation of the study does not mean that there is a causal relationship between the drug and increased suicide risk. The manufacturer has voluntarily added risks of depression, tremor, suicidality and anxiety to the product information sheets.
The risk factors are important considerations for clinicians to be be aware of, while we wait for the FDA to complete their study.